Navigation Links
Halozyme Therapeutics Names Matt Posard to Board of Directors

SAN DIEGO, March 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Matt Posard to its Board of Directors.  Mr. Posard is currently Senior Vice President and General Manager of Translational & Consumer Genomics at Illumina, Inc.


"We welcome Matt to our Board of Directors. His strategic marketing experience will complement Halozyme's Board well as we increase our commercial activities with Hylenex," said Gregory I. Frost , Ph.D., President and Chief Executive Officer at Halozyme.

Mr. Posard has over two decades of experience in strategic and product marketing. He joined Illumina in 2006 as Vice President of Global Marketing and served as Vice President of Global Sales from 2007 to 2011, leading Illumina's successful commercial entry into the life science sequencing market where it now holds significant market share alongside the company's array business. Prior to joining Illumina, he held a variety of positions with the product marketing team at Gen-Probe, Inc., helping the company attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. He also oversaw global marketing at Biosite, Inc., where he was instrumental in the successful introduction of the company's BNP congestive heart failure biomarker and its BNP co-marketing collaboration with Beckman Coulter . Mr. Posard holds a Bachelor of Arts degree in Quantitative Economics and Decision Science from the University of California, San Diego.

About Halozyme Therapeutics
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma, Intrexon, and Pfizer. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at


Investor Contact:
Kurt Gustafson
Halozyme Therapeutics

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
2. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
3. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
4. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
5. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Halozyme to Host Third Quarter Financial Results Conference Call
7. Halozyme Reports Second Quarter 2012 Financial Results
8. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
9. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
10. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
11. Halozyme Reports First Quarter 2012 Financial Results
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Trovagene, Inc. (NASDAQ: TROV ... that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled ... Annual Piper Jaffray Healthcare Conference. th ... York Palace Hotel in New York ... EST. Mr. Schuh will be available for one-on-one meetings ...
(Date:11/25/2015)... Nov. 25, 2015 USP 800 applies ... preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, physician ... The chapter also covers all entities which store, ... hospitals, other healthcare institutions, patient treatment clinics, physicians, ... --> --> What is the ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... role in boosting the profitability of pharmaceutical products, ... commercial, and regulatory/legal strategies all play a ... says GBI Research . --> ... play a key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s ... learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions ... 65 years, Brillianteen has been a treasured tradition for numerous families in the ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):